Treatment of the naive patient.

Research output: Contribution to journalArticle

Abstract

The 6th Conference on Retroviruses and Opportunistic Infections included some significant information on initial HIV therapy. Data from the Dupont 006 efavirenz (EFV)/AZT/3TC trial are provided in a table and demonstrate the excellent potency and durability of efavirenz. The Atlantic Trial compares three 3-drug regimens. Twenty-four week results are presented, including evidence that median increases in CD4 counts are similar between the groups. In addition, researchers from the conference presented 24-week data from two open trials of ABT 378 in combination with Ritonavir. This drug shows great tolerability and potency. Details from each trial are discussed.

Original languageEnglish (US)
JournalThe Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service
Volume11
Issue number2
StatePublished - 1999
Externally publishedYes

Fingerprint

efavirenz
Lopinavir
Ritonavir
Lamivudine
CD4 Lymphocyte Count
Pharmaceutical Preparations
Research Personnel
HIV
Therapeutics

Cite this

@article{38dddc41f90e440b861a3812e5da052a,
title = "Treatment of the naive patient.",
abstract = "The 6th Conference on Retroviruses and Opportunistic Infections included some significant information on initial HIV therapy. Data from the Dupont 006 efavirenz (EFV)/AZT/3TC trial are provided in a table and demonstrate the excellent potency and durability of efavirenz. The Atlantic Trial compares three 3-drug regimens. Twenty-four week results are presented, including evidence that median increases in CD4 counts are similar between the groups. In addition, researchers from the conference presented 24-week data from two open trials of ABT 378 in combination with Ritonavir. This drug shows great tolerability and potency. Details from each trial are discussed.",
author = "John Bartlett",
year = "1999",
language = "English (US)",
volume = "11",
journal = "The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service",
issn = "1551-8396",
publisher = "Johns Hopkins University Press",
number = "2",

}

TY - JOUR

T1 - Treatment of the naive patient.

AU - Bartlett, John

PY - 1999

Y1 - 1999

N2 - The 6th Conference on Retroviruses and Opportunistic Infections included some significant information on initial HIV therapy. Data from the Dupont 006 efavirenz (EFV)/AZT/3TC trial are provided in a table and demonstrate the excellent potency and durability of efavirenz. The Atlantic Trial compares three 3-drug regimens. Twenty-four week results are presented, including evidence that median increases in CD4 counts are similar between the groups. In addition, researchers from the conference presented 24-week data from two open trials of ABT 378 in combination with Ritonavir. This drug shows great tolerability and potency. Details from each trial are discussed.

AB - The 6th Conference on Retroviruses and Opportunistic Infections included some significant information on initial HIV therapy. Data from the Dupont 006 efavirenz (EFV)/AZT/3TC trial are provided in a table and demonstrate the excellent potency and durability of efavirenz. The Atlantic Trial compares three 3-drug regimens. Twenty-four week results are presented, including evidence that median increases in CD4 counts are similar between the groups. In addition, researchers from the conference presented 24-week data from two open trials of ABT 378 in combination with Ritonavir. This drug shows great tolerability and potency. Details from each trial are discussed.

UR - http://www.scopus.com/inward/record.url?scp=0033085502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033085502&partnerID=8YFLogxK

M3 - Article

C2 - 11366244

AN - SCOPUS:0033085502

VL - 11

JO - The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service

JF - The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service

SN - 1551-8396

IS - 2

ER -